- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05919810
The Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne
Study Overview
Status
Intervention / Treatment
Detailed Description
The investigators hope to evaluate the effects of oral supplements in changing intestinal health and the gut bacteria in patients with non-cystic acne vulgaris.
Acne is a chronic inflammatory condition that is estimated to affect greater than 85% of the population at some point. While antibiotics are typically used for systemic therapy, it can increase the risk for drug-resistant bacteria and shift the gut microbiome in a negative way. On the other hand, probiotics and dietary supplementation have been shown to support the gut microbiome.
In this study, participants will be randomized to either receiving a probiotic or powder supplement.
This means that participants will have an equal chance of receiving either product as half of the participants will be randomized to receive only oral probiotic, and the other half will receive oral supplement powder.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nasima Afzal
- Phone Number: 9167502463
- Email: nasima@integrativeskinresearch.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95819
- Recruiting
- Integrative Skin Science and Research
-
Contact:
- Nasima Afzal
- Phone Number: 916-750-2463
- Email: nasima@integrativeskinresearch.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects 12 years of age until 45 years of age
- The presence of mild to moderate acne based on investigator global assessment.
- Presence of at least 10 inflammatory lesions and at least 5 non-inflammatory lesions
Exclusion Criteria:
- The presence of severe acne as noted by the investigator global assessment.
- Those who are unwilling to discontinue oral probiotic-based supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
- Those who are unwilling to discontinue topical antibiotics and topical benzoyl peroxide for 2 weeks prior to enrollment
- Those who are unwilling to keep their facial regimen the same throughout the study
- Individuals who have been on an oral antibiotic for acne within the previous one month.
- Individuals who are pregnant or breastfeeding.
- Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.
- Individuals on oral contraceptive pills or progesterone or estrogen containing therapies
- Use of isotretinoin within the three months prior to enrollment.
- Individuals on finasteride or dutasteride
- Current tobacco smoker or a tobacco smoking history
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic
Daily consumption of probiotic
|
Oral probiotic
|
Experimental: Oral herbal supplement
Daily consumption of oral herbal supplement powder
|
oral herbal powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut microbiome diversity
Time Frame: 4 weeks
|
Change on the Shannon diversity of the gut microbiome
|
4 weeks
|
Sebum excretion rate
Time Frame: 4 weeks
|
Measure of skin sebum via sebumeter
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diurnal Cortisol Slope
Time Frame: 4 weeks
|
4 point salivary cortisol collections to assess diurnal slope
|
4 weeks
|
Diurnal Cortisol Slope
Time Frame: 8 weeks
|
4 point salivary cortisol collections to assess diurnal slope
|
8 weeks
|
Salivary Dihydrotestosterone
Time Frame: 4 weeks
|
Salivary collection to assess dihydrotestosterone
|
4 weeks
|
Salivary Dihydrotestosterone
Time Frame: 8 weeks
|
Salivary collection to assess dihydrotestosterone
|
8 weeks
|
Gut microbiome diversity
Time Frame: 8 weeks
|
Change on the Shannon diversity of the gut microbiome
|
8 weeks
|
Sebum excretion rate
Time Frame: 8 weeks
|
Measure of skin sebum via sebumeter
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total lesion count
Time Frame: 4 weeks
|
Safety endpoint to count inflammatory and non-inflammatory lesions
|
4 weeks
|
Total lesion count
Time Frame: 8 weeks
|
Safety endpoint to count inflammatory and non-inflammatory lesions
|
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Raja Sivamani, MD MS AP, Principal Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CB_Acne_Supp
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Diseases
-
West Virginia UniversityMary Babb Randolph Cancer Center at West Virginia University Hospitals; West...RecruitingSkin Cancer | Skin Lesion | Skin Melanoma | Tumor SkinUnited States
-
Paratek Pharmaceuticals IncCompletedInfectious Skin Disease | Bacterial Skin DiseaseUnited States
-
R2 DermatologyRecruitingSkin LesionUnited States
-
TCI Co., Ltd.Completed
-
Nexus Wise Sdn BhdJScience Consultancy PLTCompleted
-
R2 DermatologyCompleted
Clinical Trials on Probiotic
-
King's College Hospital NHS TrustCompleted
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
Centros de Investigación de Nutrición y SaludNutribioticaCompletedFunctional ConstipationSpain
-
Universiti Kebangsaan Malaysia Medical CentreUnknownHypertension | Obesity | Type 2 Diabetes Mellitus | HyperlipidemiaMalaysia
-
Maastricht University Medical CenterCompleted
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown
-
Centro Pediatrico Albina de PatinoCompletedAcute Gastroenteritis | Acute DiarrheaBolivia
-
BiocodexCompletedAcute GastroenteritisArgentina
-
Deivis de Oliveira guimaraesCompletedParkinson Disease | Alzheimer DiseaseBrazil